Telerehabilitation as Follow-up for Obesity
Condition(s) studied
Investigational drug(s) / intervention(s)
Aerobic Exercice and muscular reinforcement: Aerobic exercise and muscle strengthening to increase weekly physical activity at moderate and vigorous intensities
Study summary
The goal of this experimental study is to observed the impact of telerehabilitation modalities in obese patient after a hospitalization on physical intensity at home (MVPA). The secondary aim is to observe the evolution of clinical parameters such as anthropometric data, adherence and psychological state.
Eligibility
Primary outcome measure(s)
- MVPA — Up to 8 months
Time (min/s) of physical activity at moderate and/or vigorous intensity. This is done with a trivial accelerometer and measures with an equation (Garmin) the MVPA practice time over a week and gives a value in minutes per week. It enables us to understand whether or not a participant is achieving the recommended level of physical activity (150 min/week at moderate or vigorous intensity). - MVPA — Up to 8 months
This questionnaire by Craig et al (2003) consists of 27 questions divided into 5 parts. In each part, the participant is asked to quantify the amount of time in minutes/hours/days spent in PA. The first part comprises questions 1 to 7 and covers all physical activity practised in a professional context. The second part, questions 8 to 13, covers physical activity related to daily commuting (walking, cycling, driving, etc.) (to work, to the stores, etc.). The third part comprises questions 14 to 19 and covers activities related to housework, home maintenance, time spent with family, etc. The fourth part, questions 20 to 25, deals with physical activity related to leisure, sport and free time. Finally, the fifth section includes questions 26 to 27 and covers time spent sitting or lying down during the day.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Bernard Descottes Obesity Center | Saint-Yrieix-la-Perche | France |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06871436 on ClinicalTrials.gov ↗ ← All trials in France